- Home
- HQH vs NVCR Comparison
HQH vs NVCR Comparison
Compare HQH & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HQH | NVCR |
|---|---|---|
| Founded | 1986 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | HQH | NVCR |
|---|---|---|
| Price | $21.90 | $12.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $25.71 |
| AVG Volume (30 Days) | 156.2K | ★ 1.7M |
| Earning Date | 01-01-0001 | 10-29-2026 |
| Dividend Yield | ★ 11.56% | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ 1.09 | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | N/A | $12.91 |
| Revenue Next Year | N/A | $9.23 |
| P/E Ratio | $19.38 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $17.14 | $9.82 |
| 52 Week High | $24.85 | $21.45 |
Technical Indicators
Market Signals| Indicator | HQH | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 59.28 | 35.80 |
| Support Level | $18.88 | $11.73 |
| Resistance Level | $22.23 | $13.17 |
| Average True Range (ATR) | 0.68 | 0.81 |
| MACD | 0.16 | -0.08 |
| Stochastic Oscillator | 91.78 | 17.08 |
Price Performance
Historical ComparisonAbout HQH abrdn Healthcare Investors Shares of Beneficial Interest
abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.